Ipsen
↗Boulogne-Billancourt, France
Ipsen is a global specialty-care biopharmaceutical company focused on transformative medicines in three key therapeutic areas: Oncology, Rare Disease, and Neuroscience. The company operates with a high-growth strategy centered on external innovation, maintaining a robust pipeline of over 30 innovative programs ranging from early discovery to commercialization.
Headquartered in France, Ipsen has a significant global footprint with major R&D hubs in the U.S., France, and the U.K. The company is known for its leadership in niche markets, particularly in neuroendocrine tumors and rare liver diseases, and has recently expanded its portfolio through aggressive acquisitions and licensing deals in the ADC and T-cell engager spaces.
CLASSIFICATION
SIZE & FINANCIALS
Employees:5001-10000
Revenue:$3.5B-$4B
Founded:1929
Ownership:public
Status:operating
FUNDING
Stage:Pre-IPO
Investors:Alasol Foundation, Beech Tree S.A.
STOCK
Exchange:Euronext Paris
Ticker:IPN
Market Cap:$12.5B
PIPELINE
Stage:Commercial
Lead Drug Stage:Commercial
Modalities:Small molecule, mAb, ADC, T-cell engager, Neurotoxin, RNA-modulating
Active Trials:35
Trial Phases:Phase 1: 12 | Phase 2: 15 | Phase 3: 8 | Phase 4: 5
FDA Approvals:15
EMA Approvals:18
CORPORATE STRUCTURE
Subsidiaries:Albireo Pharma, Epizyme, Clementia Pharmaceuticals, ImCheck Therapeutics
Key Partnerships:Exelixis (Cabometyx), Skyhawk Therapeutics (Neuroscience RNA), Sutro Biopharma (ADCs), Marengo Therapeutics (T-cell engagers), Genfit (Iqirvo)
COMPETITION
Position:Leader
Competitors:Novartis, Roche, Takeda, Astellas, Cipla (Generic competitor)
LEADERSHIP
Key Executives:
David Loew - CEO
Aymeric Le Chatelier - CFO
Christelle Huguet - Head of R&D
Board Members:Marc de Garidel (Chairman), Antoine Flochel, Margaret Liu, Peter Guenter
LINKS
⚠
Is this information incorrect? This profile was AI-generated from publicly available sources and may contain errors. If you are a representative of Ipsen and believe any information on this page is inaccurate, we will promptly correct or remove it.REPORT AN ERROR
Disclaimer: IntuitionLabs.ai is not affiliated with, endorsed by, or associated with Ipsen. The information on this page was compiled using AI from publicly available sources and may be incomplete, outdated, or contain errors. We are committed to correcting inaccuracies promptly upon notice. For official information, please visit the company's website directly.